Advertisement

Topics

Myovant reports a Phase 3 success, but Wall Street isn't cheered

08:00 EDT 14 May 2019 | BioPharmaDive

Results showed Myovant's uterine fibroids drug met its goal, but comparisons to a similar treatment from AbbVie appear to have sapped investor optimism.

Original Article: Myovant reports a Phase 3 success, but Wall Street isn't cheered

NEXT ARTICLE

More From BioPortfolio on "Myovant reports a Phase 3 success, but Wall Street isn't cheered"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...